Literature DB >> 15908356

A newly discovered mycobacterial pathogen isolated from laboratory colonies of Xenopus species with lethal infections produces a novel form of mycolactone, the Mycobacterium ulcerans macrolide toxin.

Armand Mve-Obiang1, Richard E Lee, Edward S Umstot, Kristin A Trott, Timothy C Grammer, John M Parker, Brian S Ranger, Robert Grainger, Engu A Mahrous, P L C Small.   

Abstract

Mycobacterium ulcerans, the causative agent of Buruli ulcer, produces a macrolide toxin, mycolactone A/B, which is thought to play a major role in virulence. A disease similar to Buruli ulcer recently appeared in United States frog colonies following importation of the West African frog, Xenopus tropicalis. The taxonomic position of the frog pathogen has not been fully elucidated, but this organism, tentatively designated Mycobacterium liflandii, is closely related to M. ulcerans and Mycobacterium marinum, and as further evidence is gathered, it will most likely be considered a subspecies of one of these species. In this paper we show that M. liflandii produces a novel plasmid-encoded mycolactone, mycolactone E. M. liflandii contains all of the genes in the mycolactone cluster with the exception of that encoding CYP140A2, a putative p450 monooxygenase. Although the core lactone structure is conserved in mycolactone E, the fatty acid side chain differs from that of mycolactone A/B in the number of hydroxyl groups and double bonds. The cytopathic phenotype of mycolactone E is identical to that of mycolactone A/B, although it is less potent. To further characterize the relationship between M. liflandii and M. ulcerans, strains were analyzed for the presence of the RD1 region genes, esxA (ESAT-6) and esxB (CFP-10). The M. ulcerans genome strain has a deletion in RD1 and lacks these genes. The results of these studies show that M. liflandii contains both esxA and esxB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908356      PMCID: PMC1111873          DOI: 10.1128/IAI.73.6.3307-3312.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  29 in total

1.  Identification using LC-MSn of co-metabolites in the biosynthesis of the polyketide toxin mycolactone by a clinical isolate of Mycobacterium ulcerans.

Authors:  Hui Hong; Paul J Gates; James Staunton; Tim Stinear; Stewart T Cole; Peter F Leadlay; Jonathan B Spencer
Journal:  Chem Commun (Camb)       Date:  2003-11-21       Impact factor: 6.222

2.  A new mycobacterial infection in man.

Authors:  P MacCALLUM; J C TOLHURST
Journal:  J Pathol Bacteriol       Date:  1948-01

3.  Suspension cultivation of Mycobacterium ulcerans for the production of mycolactones.

Authors:  L D Cadapan; R L Arslanian; J R Carney; S M Zavala; P L Small; P Licari
Journal:  FEMS Microbiol Lett       Date:  2001-12-18       Impact factor: 2.742

4.  Uptake and cellular actions of mycolactone, a virulence determinant for Mycobacterium ulcerans.

Authors:  D Scott Snyder; P L C Small
Journal:  Microb Pathog       Date:  2003-02       Impact factor: 3.738

5.  The primary mechanism of attenuation of bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue.

Authors:  Tsungda Hsu; Suzanne M Hingley-Wilson; Bing Chen; Mei Chen; Annie Z Dai; Paul M Morin; Carolyn B Marks; Jeevan Padiyar; Celia Goulding; Mari Gingery; David Eisenberg; Robert G Russell; Steven C Derrick; Frank M Collins; Sheldon L Morris; C Harold King; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

6.  Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Authors:  Alexander S Pym; Priscille Brodin; Laleh Majlessi; Roland Brosch; Caroline Demangel; Ann Williams; Karen E Griffiths; Gilles Marchal; Claude Leclerc; Stewart T Cole
Journal:  Nat Med       Date:  2003-04-14       Impact factor: 53.440

7.  Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence.

Authors:  Armand Mve-Obiang; Richard E Lee; Françoise Portaels; P L C Small
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

8.  Subtractive hybridization reveals a type I polyketide synthase locus specific to Mycobacterium ulcerans.

Authors:  Grant A Jenkin; Timothy P Stinear; Paul D R Johnson; John K Davies
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

9.  Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guérin attenuation.

Authors:  Kaeryn N Lewis; Reiling Liao; Kristi M Guinn; Mark J Hickey; Sherilyn Smith; Marcel A Behr; David R Sherman
Journal:  J Infect Dis       Date:  2002-12-02       Impact factor: 5.226

Review 10.  Mycolactones and Mycobacterium ulcerans disease.

Authors:  Tjip S van der Werf; Timothy Stinear; Ymkje Stienstra; Winette T A van der Graaf; Pamela L Small
Journal:  Lancet       Date:  2003-09-27       Impact factor: 79.321

View more
  46 in total

1.  Use of microelectronic array technology for rapid identification of clinically relevant mycobacteria.

Authors:  Maurizio Sanguinetti; Linda Novarese; Brunella Posteraro; Stefania Ranno; Elena De Carolis; Giovanni Pecorini; Barbara Lucignano; Fausta Ardito; Giovanni Fadda
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

2.  Total Synthesis of Mycolactones A and B.

Authors:  Fengbin Song; Steve Fidanze; Andrew B Benowitz; Yoshito Kishi
Journal:  Tetrahedron       Date:  2007-06-25       Impact factor: 2.457

3.  Evolution of Mycobacterium ulcerans and other mycolactone-producing mycobacteria from a common Mycobacterium marinum progenitor.

Authors:  Marcus J Yip; Jessica L Porter; Janet A M Fyfe; Caroline J Lavender; Françoise Portaels; Martha Rhodes; Howard Kator; Angelo Colorni; Grant A Jenkin; Tim Stinear
Journal:  J Bacteriol       Date:  2006-12-15       Impact factor: 3.490

4.  Highly stereoselective total synthesis of fully hydroxy-protected mycolactones A and B and their stereoisomerization upon deprotection.

Authors:  Guangwei Wang; Ning Yin; Ei-ichi Negishi
Journal:  Chemistry       Date:  2011-03-15       Impact factor: 5.236

5.  Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.

Authors:  Egídio Torrado; Alexandra G Fraga; António G Castro; Pieter Stragier; Wayne M Meyers; Françoise Portaels; Manuel T Silva; Jorge Pedrosa
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

Review 6.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

Review 7.  The chemistry and biology of mycolactones.

Authors:  Matthias Gehringer; Karl-Heinz Altmann
Journal:  Beilstein J Org Chem       Date:  2017-08-11       Impact factor: 2.883

8.  Complete genome sequence of the frog pathogen Mycobacterium ulcerans ecovar Liflandii.

Authors:  Nicholas J Tobias; Kenneth D Doig; Marnix H Medema; Honglei Chen; Volker Haring; Robert Moore; Torsten Seemann; Timothy P Stinear
Journal:  J Bacteriol       Date:  2012-11-30       Impact factor: 3.490

9.  Mycobacterium liflandii infection in European colony of Silurana tropicalis.

Authors:  Patrick Suykerbuyk; Kris Vleminckx; Frank Pasmans; Pieter Stragier; Anthony Ablordey; Hong Thi Tran; Katleen Hermans; Michelle Fleetwood; Wayne M Meyers; Françoise Portaels
Journal:  Emerg Infect Dis       Date:  2007-05       Impact factor: 6.883

10.  Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer.

Authors:  Nicholas J Tobias; Torsten Seemann; Sacha J Pidot; Jessica L Porter; Laurent Marsollier; Estelle Marion; Franck Letournel; Tasnim Zakir; Joseph Azuolas; John R Wallace; Hui Hong; John K Davies; Benjamin P Howden; Paul D R Johnson; Grant A Jenkin; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2009-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.